BAY 1003803: A Non-Steroid Glucocorticoid Receptor Modulator
BAY 1003803
non-steroid glucocorticoid receptor modulator completed Ph. I as topical agent in psoriasis from optimization of prior lead Bioorg. Med. Chem. Lett., Jun. 1, 2020 Bayer AG, Berlin, DE / AstraZeneca
Other molecules you may be interested in
BI 730357
The Boehringer RORγ antagonist, BI 730357, is an oral once-daily clinical candidate from a new compound class in development for plaque psoriasis. We highlighted two other RORγ modulators last year in February and March. While most clinical RORγ modulators have discontinued development after reaching Ph. II, BI 730357’s Ph. II trial appears [...]
AZD0284
The AstraZeneca oral RORgt inverse agonist, AZD0284 , is an inverse agonist of the nuclear receptor RORC2 (RORγt). Reviewer Chris Gampe says, “targeting the activation and function of Th17 cells has been successful for the treatment of autoimmune disease (cf. IL-17, IL-17R, IL-23 Abs). RORC2 is the transcription factor that controls Th17 [...]
remibrutinib
Remibrutinib (Novartis oral BTK-selective covalent kinase inhibitor clinical candidate)
SHR168442
The Eternity Bioscience/Shanghai Hengrui RORγ antagonist, SHR168442, is a skin-restricted, topical compound intended to treat psoriasis. As a master regulator of Th17 immune cells which are significantly involved in allergic diseases, both positive and negative oral modulators of RORγt had been hotly pursued, though many have ceased clinical [...]
LEO 39652
LEO 39652 (LEO Pharma “dual-soft” topical PDE4 inhibitor soft drug clinical candidate)